

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

PENN-0798

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/049562

INTERNATIONAL APPLICATION NO.
PCT/US00/21789

INTERNATIONAL FILING DATE
10 August 2000

PRIORITY DATE CLAIMED
19 August 1999

TITLE OF INVENTION

METHODS AND COMPOSITIONS FOR MODULATING SOMATOLACTOGENIC FUNCTIONS

APPLICANT(S) FOR DO/EO/US

CLEVENGER, Charles V. and RYCYZYN, Michael A.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

1) Courtesy copy of the International Application;

2) Statement to support filing and submission in accordance with 37 CFR 1.821-1.825;

3) Response to Written Opinion;

4) Return post card.

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 107049562	INTERNATIONAL APPLICATION NO. PCT/US00/21789	ATTORNEY'S DOCKET NUMBER PENN-0798
--	--	--

24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :				CALCULATIONS PTO USE ONLY	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$100.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	10 - 20 =	0	x \$18.00	\$0.00	
Independent claims	4 - 3 =	1	x \$84.00	\$84.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$184.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$92.00	
SUBTOTAL =				\$92.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$92.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$92.00	
				Amount to be: refunded	\$
				charged	\$

- a. ☐ A check in the amount of _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-1619 in the amount of \$92.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1619 A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:	
Jane Massey Licata, Registration No. 32,257 Kathleen A. Tyrrell, Registration No. 38,350 Licata & Tyrrell P.C. 66 East Main Street Marlton, New Jersey 08053 Tel: 856-810-1515 Fax: 856-810-1454	<div style="text-align: center;"> </div> SIGNATURE Jane Massey Licata NAME 32,257 REGISTRATION NUMBER February 14, 2002 DATE

10044562 10/049562

JC12 Rec'd PCT/PTO 14 FEB 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: PENN-0798
Inventors: Clevenger and Ryczyn
Serial No.: Not yet assigned
Filing Date: Herewith
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: Methods and Compositions for Modulating
Somatolactogenic Functions

"Express Mail" Label No EV 017478452US
Date of Deposit - February 14, 2002

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Assistant Commissioner
for Patents, Washington, DC 20231

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

BOX PCT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR § 1.821 THROUGH 1.825

- (XX) I hereby state, in accordance with the requirements of 37
C.F.R. §1.821(f), that the contents of the paper and computer
readable copies of the Sequence Listing, submitted in
accordance with 37 CFR §1.821(c) and (e), respectively are
the same.
- () I hereby state that the submission filed in accordance with
37 CFR §1.821(g) does not include new matter.
- (XX) I hereby state that the submission filed in accordance with
37 CFR §1.821(h) does not include new matter or go beyond the
disclosure in the international application as filed.

- () I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: February 14, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Methods and Compositions for Modulating Somatolactogenic
Functions

Introduction

This invention was supported in part by funds from
5 the U.S. government (NIH Grant No. R01CA69294 and
R01DK50771) and the U.S. government may therefore have
certain rights in the invention.

Background of the Invention

The somatolactogenic hormones prolactin (PRL) and
10 growth hormone (GH) are necessary for the full growth and
maturation of vertebrate species.

Prolactin (PRL) was originally identified as a
neuroendocrine hormone of pituitary origin. PRL expression
has also been detected in the decidua, breast and T-
15 lymphocytes (Clevenger, C.V. and Plank, T.L. J. Mammary
Gland Biol. Neoplasia 1997 2:59-68; Mershon et al.
Endocrinology 1995 136:3619-3623; DiMattia et al.
Endocrinology 1986 122:2508-2517; Ginsburg, E. and
Vonderhaar, B.K. Cancer Res. 1995 55:2591-2595; Gellersen
20 et al. Mol. Endocrinol. 1994 8:356-373; Clevenger et al.
Proc. Natl Acad. Sci. USA 1990 87:6460-6464; Montgomery et
al. Biochem. Biophys. Res. Commun. 1987 145:692-698). A
primary function of this hormone lies within the breast.
However, functional pleiotropism of this peptide with
25 regard to reproduction, osmoregulation and behavior has
also been recognized (Nicoll, C.S. Handbook of Physiology;
Section 7: Endocrinology, pp. 253-292, Washington, D.C.:
American Physiology Society. 1974). Several lines of
evidence have also indicated an immunoregulatory role for
30 this peptide (Clevenger et al. Journal of Endocrinology
1998 157:187-197; Weigent, D.A. Pharmacol. Ther. 1996
69:237-257). Structural analysis of PRL has revealed it to
be related to members of the cytokine/hematopoietin family
which also includes growth hormone, erythropoietin,
35 granulocyte-macrophage colony stimulating factor (GM-CSF)

WO 01/13113

PCT/US00/21789

-2-

and interleukins 2-7 (Bazan, J.F. Immunol. Today 1990
11:350-354)

The pleiotropic actions of PRL are mediated through
its receptor (PRLr), a member of the superfamily of type I
5 cytokine receptors. PRLr is present on numerous tissues
including mammary epithelia, T and B lymphocytes and
macrophages (Dardenne et al. Endocrinology 1994 134:2108-
2114; Pellegrini et al. Mol. Endocrinol. 1992 6:1023-1031).
Acting through its receptor, PRL signaling stimulates cell
10 proliferation, survival and cellular differentiation in a
tissue- and microenvironment-dependent manner. In the
mammary and immune systems, PRL is believed to act at the
endocrine, paracrine, and autocrine levels in regulating T-
lymphocyte proliferation and survival (Gala, R.R. PSEBM
15 1991 198:513-527; Yu-Lee, L.Y. Proceedings of the Society
for Experimental Biology and Medicine 1997 215:35-52;
Kooijman et al. Adv. Immunol. 1996 63:377-454; Prystowski,
M.B. and Clevenger, C.V. Immunomethods 1994 5:49-55) and
the terminal maturation of mammary tissues (Kelly et al.
20 Rec. Prog. Horm. Res. 1993 48:123-164; Shiu et al. Rec.
Prog. Horm. res. 1987 43:277-289). PRL is also believed to
act as both an endocrine and autocrine/paracrine
progression factor for mammary carcinoma in both rodents
and humans (Welsch, C.W. Cancer Res. 1985 45:3415-3443;
25 Welsch, C.W. and Nagasawa, H. Cancer Res. 1977 37:951-963;
Manni et al. Cancer Res. 1986 37:951-963; Malarkey et al.
J. Clin. Endocrinol. Metab. 1983 56:673-677; Clevenger et
al. Am. J. Pathol. 1995 146:1-11; Fields et al. Lab.
Invest. 1993 68:354-360; Ormandy et al. J. Clin.
30 Endocrinol. Metab. 1997 82:3692-3699; and Mertani et al.
Int. J. Cancer 1998 79:202-22).

Pleiotropic actions of GH are also largely mediated
through a type I cytokine receptor, GHr.

Ligand-induced dimerization of PRLr and GHr activates
35 several associated signaling cascades including the Jak-

Stat, Ras-Raf, and Fyn-Vav pathways (Campbell et al. Proc. Natl Acad. Sci. USA 1994 91:5232; Clevenger et al. J. Biol. Chem. 1994 269:5559; Clevenger et al. Mol. Endocrinol. 1994 8:674; Clevenger et al. J. Biol. Chem. 1995 270:13246).

- 5 However, studies indicate that both PRL and GH are internalized via an endosomal-like pathway and transported across the endoplasmic reticulum (ER) and nuclear envelopes (Clevenger et al. Endocrinology 1990 127:3151; Rao et al. J. Cell Physiol. 1995 163:266). This process is referred
10 to as nuclear retrotranslocation. The mechanism of this retrotranslocation, and the nuclear action of these somatolactogenic hormones, however, is not well understood.

- Both PRL and GH lack enzymatic activity. These hormones also contain no nuclear translocation signal.
15 Thus, for PRL and GH to act within the nucleus, they must do so through a binding partner or chaperone.

- CypB is a member of the cyclophilin family of cis-trans peptidyl prolyl isomerases (PPI) (Price et al. Proc. Natl Acad. Sci. USA 1991 88:1903; Ruhlmann, A. and
20 Nordheim, A. Immunobiol. 1997 198:192; Resch, K. and Szamel, M. Int. J. Immunopharmac. 1997 19:579). This family of proteins was initially identified as the binding partners for the immunosuppressive agent cyclosporine (CsA). CsA interacts with the cyclophilin with high
25 affinity, inhibiting their PPI activity and the action of the phosphatase calcineurin, necessary for NF/AT-transactivated expression of IL-2 (Kronke et al. Proc. Natl Acad. Sci. USA 1984 81:5214; Liu et al. Cell 1991 55:807; Friedman, J. and Weissman, I. Cell 1991 66:799; McCaffrey
30 et al. J. Biol. Chem. 1993 268:3747; Bram, R.J. and Crabtree, G.R. Nature 1994 371:355; Bram et al. Mol. Cell Biol. 1993 13:4760). Structurally CypB is a β -barrel protein containing both N-terminal ER-leader and putative nuclear translocation signal sequences and C-terminal ER-
35 retention sequences (Allain et al. J. Immunol. Meth. 1995

178:113; Mariller et al. Biochem. Biophys. Acta 1996
1293:31). CypB has been observed in the ER and nucleus,
and can be found in appreciable levels in blood (150 ng/ml)
and breast milk (Hirada et al. Cell 1990 63:303; Price et
5 al. Proc. Natl Acad. Sci. USA 1994 91:3931). Cyclophilins,
via their PPI activity, facilitate protein folding and have
been shown to contribute to the maturation of several
proteins, including carbonic anhydrase and the HIV
glycoprotein Gag (Taylor et al. Prog. Biophys. Molec. Biol.
10 1997 67:155; Streblow et al. Virology 1998 245:197).
Despite these insights, the physiologic function of CypB
has remained uncertain.

It has now been found that cyclophilin B (CypB)
interacts specifically with somatolactogenic hormones, PRL
15 and GH, as a chaperone mediating the transport, maturation
and/or function of these proteins.

Summary of the Invention

An object of the present invention is to provide
methods of modulating somatolactogenic function in an
20 animal comprising administering to the animal an effective
amount of a composition containing cyclophilin B or a
mutant or inhibitor thereof.

Another object of the present invention is to provide
compositions for modulating somatolactogenic function in an
25 animal comprising cyclophilin B or a mutant or inhibitor
thereof and a pharmaceutically acceptable vehicle.

Another object of the present invention is to provide
a method of identifying compounds which inhibit
somatolactogenic functions associated with PRL and GH which
30 comprises assessing the ability of a test compound to
inhibit the interaction of cyclophilin B with PRL or GH.

Yet another object of the present invention it to
provide methods and reagents for diagnosing diseases
associated with somatolactogenic functions in patients by
35 detecting levels of cyclophilin B in the patients.

Detailed Description of the Invention

Somatolactogenic hormones including GH and PRL have been implicated in the development of breast and prostate cancer, growth, and in the immune response. It has now
5 been found that the co-administration of wild-type CypB with somatolactogenic hormones including GH and PRL augments the function of these proteins. Further, it has been found that the generation of appropriate mutants of CypB can inhibit the function of these hormones.

10 CypB was confirmed to interact directly with somatolactogenic hormones such as PRL and GH. In these experiments, epitope-tagged forms of both proteins were expressed by recombinant techniques and purified to >95%. Co-immunoprecipitation studies performed on the admixed
15 proteins revealed that the introduction of either reducing agent or divalent cation facilitated the direct interaction of CypB with PRL. The addition of CSA, at a therapeutic concentration, was found to enhance the interaction approximately ten-fold, indicating that PRL
20 does not interact with the PPI pocket in CypB that engages CSA. Instead, additional experiments with GST-CypB chimera indicate that PRL binds to the C-terminus of CypB. A recombinant form of the highly homologous cyclophilin family member CypA failed to interact with PRL, further
25 confirming the specific nature of the CypB-PRL interaction. Additional *in vivo* confirmation of the CypB-PRL interaction was obtained by the direct co-immunoprecipitation of PRL with CypB from human serum, and the binding of serum PRL to a sepharose-conjugated, recombinant CypB.

30 The effect of exogenous CypB on PRL-driven proliferation was examined with the rat Nb2 T-cell and the human T47D breast cancer line. In response to exogenous PRL, Nb2 cells demonstrate dose-dependent growth (Gout et al. Cancer Res. 1980 40:2437). The addition of CypB into
35 the PRL-containing Nb2 culture medium resulted in up to an

eight-fold enhancement of PRL-driven growth as compared to Nb2 cultures that received only PRL. This dose-dependent biphasic effect was most prominent at physiologic concentrations (5-10 mM) of CypB and PRL (50 pM) found in human serum. Similar proliferative responses were observed with the T47D line. The co-addition of CypA into Nb2 cell cultures did not result in any potentiation PRL-driven growth. To determine the effect of CypB on cellular growth driven by the larger family of cytokines, to which PRL belongs, proliferation driven by interleukin-2 (IL-2), IL-3 and GH was examined. Neither IL-2- nor IL-3-driven proliferation was altered by the addition of varying concentration of CypB, whereas physiological concentrations of CypB enhanced GH-driven proliferation forty-fold as compared to cultures receiving similar concentrations of GH alone. Thus, as demonstrated herein somatolactogenic function is significantly potentiated in a synergistic manner by physiologic concentrations of CypB.

Experiments were performed to examine the ability of CypB to enhance nuclear retrotranslocation of PRL, and thereby PRL-driven proliferation. Indirect immunofluorescence of T47D human breast cancer cells labeled with an anti-PRL antibody has been documented to produce a diffuse, speckled pattern of cytosolic immunofluorescence in the majority of cells, consistent with the internalization of PRL into endosomal-like vesicles (Perrot-Applanat et al. J. Cell Sci. 1997 110:1123). In these experiments, however, inclusion of the co-mitogen epidermal growth factor (EGF) into the defined T47D culture medium induced demonstrable anti-PRL immunofluorescence over approximately 10% of the T47D nuclei. These findings are consistent with previous reports in an L2 cloned T-cell line, that revealed a requirement for co-mitogenic stimulation before appreciable nuclear retrotranslocation of PRL was detectable (Clevenger

-7-

et al. Science 1991 253:77; Clevenger et al. Proc. Natl Acad. Sci. 1990 87:6460). These experiments also demonstrated that nuclear retrotranslocation of PRL was significantly enhanced by inclusion of CypB into this
5 defined medium, resulting in 95-100% of the T47D nuclei exhibiting anti-PRL immunofluorescence. These data have been confirmed at the biochemical level by the demonstration of intranuclear PRL-CypB complexes by co-immunoprecipitation analysis. These data therefore
10 indicate that CypB acts as a reverse chaperone, facilitating the retrotranslocation of PRL in to the nucleus.

Examination of the amino acid sequence of CypB (GenBank Accession Number NM 000942; SEQ ID NO: 1) revealed
15 a putative nuclear translocation signal in its amino-terminus that is absent in CypA. The role of this sequence in the CypB-mediated retrotranslocation of PRL, and its associated enhancement of growth was tested by mutagenic approaches. The putative nuclear localization sequence of
20 CypB was deleted in the mutant CypB-NT. Comparison of purified wild-type CypB and CypB-NT revealed identical levels of PPI activity, confirming that the mutant protein was appropriately folded and bioactive. Deletion of the nuclear localization sequence did not affect the
25 interaction of PRL with the CypB-NT. However, inclusion of CypB-NT into T47D culture medium did not enhance the nuclear retrotranslocation of PRL, as illustrated by a complete absence of detectable anti-PRL immunofluorescence in any nucleus. CypB also failed to enhance PRL-induced
30 proliferation, despite its ability to interact with PRL. Taken together, these data indicate a role of the N-terminus of CypB in the nuclear retrotransport of PRL and link this to the CypB-associated potentiation of PRL-induced proliferation.

Three additional mutants have also been generated. These include a CypB mutant which lacks the carboxy terminus, referred to as CypB-AIAKE, and two point mutations with the enzymatic pocket (R63A and F68A) of CypB rendering it enzymatically inactive. These mutants are also expected to alter somatolactogenic action.

The present invention relates to methods and compositions for modulating somatolactogenic functions via this interaction of CypB with somatolactogenic hormones.

10 In one embodiment of the present invention, a composition comprising CypB in a pharmaceutically acceptable vehicle can be administered to an animal in an amount effective to augment the function of somatolactogenic hormones including GH and PRL. Specifically, compositions comprising CypB can

15 be used to enhance the immunostimulatory properties of GH and PRL in the treatment of immunosuppression (i.e. conditions such as HIV). Co-administration of CypB can also be used to augment the action of GH in the treatment of short-stature, muscle wasting, and osteoporosis.

20 Alternatively, a composition comprising a mutant of CypB with dominant negative action such as CypB-NT or an inhibitor of CypB that interferes with its effects with the somatolactogenic hormones and a pharmaceutically acceptable vehicle can be administered to an animal in an amount

25 effective to block the action of PRL and GH. Compositions comprising a CypB mutant or inhibitor of CypB interaction with somatolactogenic hormones can be used in the treatment of breast and prostate cancer, and in the treatment of conditions associated with excess PRL or GH such as

30 pituitary adenomas which can lead to hyperprolactinemia or gigantism/acromegaly. Certain pathologic conditions including, but not limited to, HIV and cancer, can alter the body's levels of CypB thereby resulting in an immunosuppressed state. Thus, compositions of the present

invention can also be used in the treatment of these immunosuppressed states.

Appropriate doses of CypB and mutants or inhibitors thereof effective in augmenting or inhibiting

5 somatolactogenic hormones to be administered to animals can be determined based upon data from cell culture experiments such as those described herein. Determination of effective doses from such data is performed routinely by those of skill. In a preferred embodiment, CypB and mutants thereof

10 are administered intravenously or intramuscularly. When used to augment somatolactogenic function, it is preferred that the dosage of CypB administered result in a serum concentration level of CypB similar to normal healthy individuals, i.e. 100-150 ng/ml. To inhibit

15 somatolactogenic function in an animal via administration of a mutant CypB or an inhibitor, higher serum concentrations are preferred. Pharmaceutically acceptable vehicles for use in compositions of the present invention are also well known in the art.

20 Also provided in the present invention is a method of identifying potential new drugs which inhibit somatolactogenic functions by identifying test compounds which inhibit the interaction of CypB with somatolactogenic hormones such as PRL or GH. Test compounds which inhibit

25 the interaction of CypB with somatolactogenic hormones are expected to inhibit somatolactogenic functions. Thus, such test compounds should be useful as drugs in the treatment of breast and prostate cancer and conditions associated with excess PRL or GH. In one embodiment, test compounds

30 with this inhibitory activity are identified in accordance with cell culture methods described herein. However, as will be obvious to those of skill in the art upon this disclosure, more rapid screening assays to identify compounds which inhibit this interaction can also be

35 developed.

The present invention also relates to a method and reagent for use in diagnosing diseases associated with abnormal somatolactogenic functions. In these methods, the level of cyclophilin B in a biological sample obtained from a patient is determined. In one embodiment, levels are determined via an immunoassay using an anti-cyclophilin B antibody. Preferably, the biological sample comprises blood, serum or plasma. The levels of cyclophilin B determined in the patient are then compared to levels of cyclophilin B in biological samples of normal individuals. Levels of cyclophilin B in the patient which are lower than levels in normal individuals are indicative of diseases or conditions wherein somatolactogenic function must be augmented. Levels of cyclophilin B in the patient which are higher than levels of cyclophilin B in normal individuals are indicative of diseases or conditions wherein somatolactogenic function must be inhibited.

The following nonlimiting examples are provided to further illustrate the present invention.

20 EXAMPLES

Example 1: Generation of CypB DNA Constructs and Protein

Full length CypB DNA was generated by PCR from an insert isolated in a yeast two-hybrid screen using specific primers containing Kpn1 and Xho1 sites (5'-3-):

25 CGGGTACCACCATGATGAAGGTGCTCCTTGCCGCGCC (SEQ ID NO: 2) and CGCTCGAGCTCCTTGCGGATGCCAAAGGG (SEQ ID NO: 3), with the forward primer containing a Kozak signal sequence. Full length PRL cDNA was generated by PCR using a specific forward primer containing a Kpn1 site and Kozak signal

30 sequence: CGGGTACCACCATGATGAACATCAAAGGATCGCCATGGAAAGGG (SEQ ID NO: 4); and a reverse primer containing a Xho1 site and a myc-tag with two stop codons immediately following the tag:

CGCTCGAGTTACTACAGATCCTCTTCTGAGATGAGTTTTTGTTCGAGTTGTTGTTGTG

35 GATGAT (SEQ ID NO: 5). PCR products were purified,

Example 2: Detection of PRL-CypB Complexes by
25 Immunoprecipitation

Purified His-tagged CypB and myc-tagged PRL (10 ng each) were admixed in binding buffer (10 mM Tris pH 7.6, 125 mM NaCl, 10% glycerol) in the presence or absence of 5 mM CaCl₂, 1.5 mM 2ME or 50 nM cyclosporin A. Samples were
30 rotated for three hours at room temperature. Complexes were immunoprecipitated by the addition of 1 µg of polyclonal anti-histidine antibody (#sc-803, Santa Cruz Biotech) for one hour followed by roatation for one hour with 50 µl Protein-A beads. Precipiated complexes were
35 separated by 15% SDS-PAGE and transferred to PVDF.

Immunoblots were blocked for one hour at room temperature with 5% milk in PBS containing 1% TWEEN-20 (PBST) and immunoblotted with a monoclonal anti-myc antibody (1:1000, mAb 9E10) for one hour. Immunoblots were analyzed by

5 incubation with an anti-mouse secondary antibody conjugated to horseradish peroxidase (1:2000, Boehringer Mannheim) for one hour followed by incubation with ECL Plus (Amersham Pharmacia Biotech) and exposure to Biomax film (Kodak).

Example 3: Use of Nb2 Cell Cultures to Assess CypB

10 **Modulation of Somatolactogenic Action**

Nb2-cells (5×10^4 ; PRL-dependent, rat T-lymphoma) were plated in each well of 96 well plates in a defined DMEM-serum free medium (0.1 mM 2-mercaptoethanol, 1% penicillin/streptomycin, and 1% ITS+ (Calbiochem)). Cells

15 were rested for 24 hours at 37°C in this defined medium in the absence of PRL before the addition of 5-500 pM PRL (either as human pituitary isolated PRL, National Hormone and Pituitary Program, NIDDK; recombinant human PRL from *E. coli*, Genzyme; or recombinant human PRL from *Drosophila* S2

20 cells) alone or premixed with 1-2000 fold excess of purified CypB. Parallel studies were performed using human pituitary-derived GH (National Hormone and Pituitary Program, NIDDK). Cultures were incubated for 48 hours at 37°C and proliferation was evaluated by the addition of 0.5

25 μ Ci of 3 H-thymidine for four hours followed by harvesting and scintillography. When stimulated with PRL alone, Nb2 cells yield sigmoid shaped growth curves that plateau at approximately 2 ng PRL/ml.

Example 4: Generation and Expression of CypB-NT mutant

30 CypB-NT was generated by overlapping PCR mutagenesis. The forward CypB primer containing the KpnI Site and Kozak signal sequence was combined with the reverse primer (5'-3') AAATACACCTTGGCCGCAGAAGGTCCCGG (SEQ ID NO: 6), while the reverse primer containing the XhoI site was combined with

35 the forward primer (5'-3')

WO 01/13113

PCT/US00/21789

-13-

GCGGCCAAGGTGTATTTTGACCTACGAATTGGA (SEQ ID NO: 7). the
resulting PCR products were purified, mixed and re-
amplified with the forward and reverse CypB primers. Their
resulting PCR product, lacking amino acid residues 2-12 of
5 the mature peptide while retaining the leader sequence was
confirmed by dideoxynucleotide sequencing. This PCR-
derived mutant was digested, cloned into pAc5/V5-HisA,
expressed in the Drosophila Expression Systems and purified
as described in Example 1.

10

What is Claimed is:

1. A composition for modulating somatolactogenic function comprising:
 - (a) cyclophilin B, a mutant of cyclophilin B or an
5 inhibitor of the interaction of cyclophilin B with a somatolactogenic hormone; and
 - (b) a pharmaceutically acceptable vehicle.
2. The composition of claim 1 wherein the mutant of cyclophilin B is CypB-NT.
- 10 3. A method for modulating somatolactogenic function in an animal comprising administering to the animal the composition of claim 1.
4. The method of claim 3 wherein somatolactogenic function in the animal is augmented by administering a
15 composition comprising cyclophilin B and a pharmaceutically acceptable vehicle.
5. The method of claim 3 wherein somatolactogenic function in the animal is inhibited by administering a composition comprising a cyclophilin B mutant or an
20 inhibitor of the interaction of cyclophilin B with a somatolactogenic hormone and a pharmaceutically acceptable vehicle.
6. The method of claim 5 wherein the cyclophilin B mutant is CypB-NT.
- 25 7. A method of identifying test compounds as inhibitors of somatolactogenic functions comprising assessing the ability of a test compound to inhibit interaction of cyclophilin B with a somatolactogenic hormone.
- 30 8. The method of claim 6 wherein the somatolactogenic hormone is prolactin.
9. A method for diagnosing diseases associated with abnormal somatolactogenic functions comprising:
 - (a) obtaining a biological sample from a patient:
 - 35 (b) determining levels of cyclophilin B in the

biological sample; and

- (c) comparing the determined cyclophilin B levels in the patient with cyclophilin B levels in a biological sample of normal individuals wherein levels of cyclophilin B in the patient which are lower than levels in normal individuals are indicative of diseases or conditions wherein somatolactogenic function must be augmented while levels of cyclophilin B in the patient which are higher than levels of cyclophilin B in normal individuals are indicative of diseases or conditions wherein somatolactogenic function must be inhibited.

10. The method of claim 9 wherein levels of cyclophilin B are determined via an immunoassay using an anti-cyclophilin B antibody.

PENN-0723

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/13113 A1

(51) International Patent Classification⁷: G01N 33/53,
C12N 9/00, A61K 38/00

Michael, A.; 27 E. Central Avenue, #P-6, Paoli, PA 19301
(US).

(21) International Application Number: PCT/US00/21789

(74) Agents: LICATA, Jane, Massey et al.; Law Offices of
Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053
(US).

(22) International Filing Date: 10 August 2000 (10.08.2000)

(25) Filing Language: English

(81) Designated States (*national*): AU, CA, JP.

(26) Publication Language: English

(30) Priority Data:
60/149,752 19 August 1999 (19.08.1999) US

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(71) Applicant: THE TRUSTEES OF THE UNIVERSITY
OF PENNSYLVANIA [US/US]; Center for Technology
Transfer, Suite 300, 3700 Market Street, Philadelphia, PA
19107 (US).

Published:
— With international search report.

(72) Inventors: CLEVINGER, Charles, V.; 335 Winding
Way, Merion Station, PA 19066 (US). RYCYZYN,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/13113 A1

(54) Title: METHODS AND COMPOSITIONS FOR MODULATING SOMATOLACTOGENIC FUNCTIONS

(57) Abstract: Compositions containing cyclophilin B, mutants of cyclophilin B or inhibitors of cyclophilin B and methods of using these compositions to modulate somatolactogenic function are provided.

10/049562

JC13 Rec'd PCT/PTO 14 FEB 2002

PCT/US00/21789

WO 01/13113

SEQUENCE LISTING

<110> Clevenger, Charles V.
Ryczyn, Michael A.
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

<120> Methods and Compositions for Modulating
Somatolactogenic Functions

<130> PENN-0723

<140>
<141>

<150> 60/149,752
<151> 1999-08-19

<160> 7

<170> PatentIn Ver. 2.1

<210> 1
<211> 216
<212> PRT
<213> Homo sapiens

<400> 1
Met Leu Arg Leu Ser Glu Arg Asn Met Lys Val Leu Leu Ala Ala Ala
1 5 10 15
Leu Ile Ala Gly Ser Val Phe Phe Leu Leu Leu Pro Gly Pro Ser Ala
20 25 30
Ala Asp Glu Lys Lys Lys Gly Pro Lys Val Thr Val Lys Val Tyr Phe
35 40 45
Asp Leu Arg Ile Gly Asp Glu Asp Val Gly Arg Val Ile Phe Gly Leu
50 55 60
Phe Gly Lys Thr Val Pro Lys Thr Val Asp Asn Phe Val Ala Leu Ala
65 70 75 80
Thr Gly Glu Lys Gly Phe Gly Tyr Lys Asn Ser Lys Phe His Arg Val
85 90 95
Ile Lys Asp Phe Met Ile Gln Gly Gly Asp Phe Thr Arg Gly Asp Gly
100 105 110

WO 01/13113

PCT/US00/21789

Thr Gly Gly Lys Ser Ile Tyr Gly Glu Arg Phe Pro Asp Glu Asn Phe
115 120 125

Lys Leu Lys His Tyr Gly Pro Gly Trp Val Ser Met Ala Asn Ala Gly
130 135 140

Lys Asp Thr Asn Gly Ser Gln Phe Phe Ile Thr Thr Val Lys Thr Ala
145 150 155 160

Trp Leu Asp Gly Lys His Val Val Phe Gly Lys Val Leu Glu Gly Met
165 170 175

Glu Val Val Arg Lys Val Glu Ser Thr Lys Thr Asp Ser Arg Asp Lys
180 185 190

Pro Leu Lys Asp Val Ile Ile Ala Asp Cys Gly Lys Ile Glu Val Glu
195 200 205

Lys Pro Phe Ala Ile Ala Lys Glu
210 215

<210> 2
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 2
cgggtaccac catgatgaag gtgctccttg cgcgcc 38

<210> 3
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic

<400> 3
cgctcgagct ccttgccgat gccaaagg 29

<210> 4
<211> 44

WO 01/13113

PCT/US00/21789

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 4

cggtaccac catgatgaac atcaaaggat cgccatggaa aggg

44

<210> 5

<211> 65

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 5

cgctcgagtt actacagatc ctcttctgag atgagttttt gttcgagtt gttggtgtgg 60
atgat 65

<210> 6

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 6

aaatacacct tggccgcaga aggtcccgg

29

<210> 7

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic

<400> 7

gcggccaagg tgtattttga cctacgaatt gga

33

JUL 7 2002 11:21AM

JUL 7 2002 9:44AM
Express Mail Label No.

NO. 471

P. 2 of 2

NO. 470

P. 2

Page 1 of 3

Docket No.
PENN-0798

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

METHODS AND COMPOSITIONS FOR MODULATING SOMATOLACTOGENIC FUNCTIONS

the specification of which

(check one)

- ☐ is attached hereto.
- ☒ was filed on 10 August 2000 as United States Application No. or PCT International Application Number PCT/US00/21789 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

JUL 7 2002 11:21AM
JUL 1 2002 9:44AM

NO. 471 P. 3
NO. 470 P. 3

Page 2 of 3

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

<u>60/149,752</u>	<u>August 19, 1999</u>
(Application Serial No.)	(Filing Date)
<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)
<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

JUL 7 2002 11:22AM

SA Douglas Cines, M.D.

1000445562 11/03/02

NO. 471 P. 4
215-573-2016
U. 268 P. 4 V. 03

Page 3 of 3

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Send Correspondence to: Licata & Tyrrell, P.C.
66 East Main Street
Marlton, N.J. 08053

Direct Telephone Calls to: (name and telephone number)
Jane Massey Licata, 856-810-1515

1-50

Full name of sole or first inventor	Charles Clavenger
Sole or first inventor's signature	<i>Charles Clavenger</i> Date 7/18/02
Residence	Merion Station, PA PA
Citizenship	US
Post Office Address	335 Winding Way
	Merion Station, PA 19066

2-00

Full name of second inventor, if any	Michael A. Ryczyn
Second inventor's signature	<i>Michael A. Ryczyn</i> Date
Residence	Paoli, PA PA
Citizenship	US
Post Office Address	27 East Central Avenue, Apt. #9-6
	Paoli, PA 19301

JUL 7 2002 11:22AM

JUL 7 2002 9:44AM

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

Send Correspondence to: Licata & Tyrrell P.C.
66 East Main Street
Marlton, N.J. 08053

Direct Telephone Calls to: (name and telephone number)
Jane Massey Licata, 856-810-1515

Full name of sole or first inventor Charles Clavenger	
Sole or first inventor's signature	Date
Residence Merlon Station, PA	
Citizenship US	
Post Office Address 335 Winding Way Merlon Station, PA 19066	

Full name of second inventor, if any Michael A. Ryeyayn	
Second inventor's signature	Date 7-8-02
Residence Paoli, PA	
Citizenship US	
Post Office Address 27 East Central Avenue, Apt. #E-6 Paoli, PA 19301	